Immunic, Inc. develops novel oral therapies for neurologic diseases, with a lead program, vidofludimus calcium (IMU-838), focused on multiple sclerosis. Company news commonly covers clinical and scientific presentations, patent protection for vidofludimus calcium, pipeline updates, and corporate communications tied to its late-stage development strategy.
Updates also include governance changes, board and executive appointments, Nasdaq listing compliance, capital actions such as its reverse stock split, and investor conference participation. Immunic's pipeline references additional earlier-stage programs, including IMU-856 and IMU-381, tied to neurodegenerative, chronic inflammatory, and autoimmune-related disease areas.
Immunic (IMUX) granted inducement stock options covering 12,900 common shares to three new employees on October 1, 2026.
The Compensation Committee approved the awards under the 2026 Inducement Equity Compensation Plan as an inducement to begin employment, pursuant to Nasdaq Listing Rule 5635(c)(4). The options vest over time: 25% vest on the first anniversary of each employee's applicable hire date, with the remainder vesting monthly in 36 equal installments. Each installment is subject to the employee's continued employment on the vesting date.
Immunic (IMUX) will present four abstracts on investigational vidofludimus calcium at MSToronto2026 in Toronto, October 21–23, 2026.
Phase 2 CALLIPER open-label extension data favored continuous treatment over switching from placebo for disability outcomes through extension week 48. Trends toward lower risk of 24-week confirmed disability worsening persisted, improvement occurred more frequently, and discontinuation remained low.
A post-hoc analysis found significantly reduced Epstein-Barr virus-specific immune signatures versus placebo; reductions across both treatment arms were associated with better cognitive test performance. Preclinical findings linked neuronal survival to Nurr1, a protein involved in gene regulation. A proposed measure combining disability worsening and improvement produced statistically significant CALLIPER results, with similar findings using another statistical method.
Immunic (Nasdaq: IMUX) granted inducement stock options covering 196,350 common shares to seven new employees between September 14 and September 28, 2026.
The Compensation Committee approved the awards under the 2026 Inducement Equity Compensation Plan as an inducement to begin employment, pursuant to Nasdaq Listing Rule 5635(c)(4). For each employee, 25% of the options vest on the first anniversary of the applicable hire date. The remainder vest monthly in 36 equal installments, with each vesting date subject to continued employment.
Immunic (IMUX) will host a virtual R&D day focused on relapsing multiple sclerosis on Wednesday, September 9, 2026, at 11:00 am ET.
Management and external MS experts Amit Bar-Or and Stephen Krieger will discuss vidofludimus calcium (IMU‑838), an investigational oral small molecule in Phase 3 trials for relapsing MS, ahead of expected top-line ENSURE data by the end of 2026. The company highlights vidofludimus calcium’s combination of Nurr1 activation with selective DHODH inhibition, aiming to address both neurodegenerative and inflammatory drivers of MS, and notes its prior Phase 2 therapeutic potential and favorable safety profile. The Zoom webinar will run from 11:00 am to 12:30 pm ET.
Immunic (Nasdaq: IMUX) appointed Chitrang Davé as its first Chief Data and Digital Officer, effective September 1, 2026, reporting to CEO Erik Lundgren and joining the executive leadership team. In this new C-suite role, he will build enterprise-wide data systems, analytics, AI and digital capabilities.
According to Immunic, Mr. Davé will support preparation of the data package for a potential NDA submission and commercialization of lead candidate vidofludimus calcium (IMU-838) in multiple sclerosis, as Phase 3 ENSURE trials in relapsing MS near top-line data and a confirmatory progressive MS Phase 3 program advances. He received an inducement stock option for 120,000 shares, vesting 25% on August 30, 2027 and monthly thereafter over 36 months.
Immunic (Nasdaq: IMUX) reported second quarter 2026 results and a corporate update centered on its lead MS candidate, vidofludimus calcium. The twin Phase 3 ENSURE-1 and ENSURE-2 trials in relapsing MS remain on track, with top-line data expected by the end of 2026, and a Phase 3 trial in progressive MS is planned to start later in 2026.
The company expanded its leadership team, appointing Erik Lundgren as CEO and director, Michael A. Panzara as CMO, Michael W. Bonney as Chair, and Elena Ridloff to the board. Total operating expenses were $35.3 million in Q2 2026 and $68.6 million for the first half. Q2 R&D expenses rose to $25.9 million and G&A to $9.4 million, driving a Q2 net loss of $34.1 million ($0.80 per share) and a first-half net loss of $66.7 million ($1.83 per share).
Cash and cash equivalents were $155.1 million as of June 30, 2026, which Immunic expects will fund operations into late 2027.
Immunic (Nasdaq: IMUX) has appointed Elena Ridloff, CFA, to its Board of Directors, effective August 6, 2026. The company highlights that her expertise in finance, capital markets and commercial strategy comes as it approaches pivotal Phase 3 ENSURE top-line data in relapsing multiple sclerosis (MS) and prepares for potential regulatory filings and commercialization of vidofludimus calcium.
Ridloff is currently Chief Financial Officer at Sionna Therapeutics and previously served as Executive Vice President and Chief Financial Officer at ACADIA Pharmaceuticals, where she helped raise $600 million and supported commercial and pipeline expansion. She has also held senior roles at Alexion Pharmaceuticals, BIOVISIO and Maverick Capital, and serves on the Board of Kymera Therapeutics. Immunic’s lead asset, oral vidofludimus calcium (IMU-838), is in Phase 3 trials in relapsing MS, with top-line data expected by the end of 2026 and an additional Phase 3 trial in progressive MS expected to start later in 2026.
Immunic (Nasdaq: IMUX) will participate in several investor conferences in July 2026. The company’s CEO Erik Lundgren, President/COO Jason Tardio, CMO Michael A. Panzara and VP IR Jessica Breu will join meetings and a fireside chat with investors in Boston and San Francisco.
Immunic (Nasdaq: IMUX) will join several investor, industry and scientific conferences in June 2026. Events include the H.C. Wainwright Neuro Perspectives Summit, BIO International Convention, EFMC-ACSMEDI Medicinal Chemistry Frontiers Symposium, and the European Academy of Neurology Congress.
Management will host presentations, partnering activities and investor meetings.
Immunic (Nasdaq: IMUX) will present one late-breaking and two additional posters at the 2026 CMSC Annual Meeting, sharing new phase 2 CALLIPER data for vidofludimus calcium in progressive multiple sclerosis.
Highlights include a novel unified disability endpoint, stable mood-related PROs, and safety/tolerability largely comparable to placebo over 120 weeks.